Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orchestra BioMed Holdings's quarterly market cap
increased
from Sep. 2025 ($140.03 Mil) to Dec. 2025 ($236.69 Mil) and
increased
from Dec. 2025 ($236.69 Mil) to Mar. 2026 ($249.18 Mil).
Orchestra BioMed Holdings's annual market cap
declined
from Dec. 2023 ($326.64 Mil) to Dec. 2024 ($152.78 Mil) but then
increased
from Dec. 2024 ($152.78 Mil) to Dec. 2025 ($236.69 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Orchestra BioMed Holdings's Enterprise Value for Today is $142.41 Mil.
Orchestra BioMed Holdings (NAS:OBIO) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Orchestra BioMed Holdings Market Cap Related Terms
Orchestra BioMed Holdings Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Orchestra BioMed Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orchestra BioMed Holdings Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Orchestra BioMed Holdings's Market Cap distribution charts can be found below:
* The bar in red indicates where Orchestra BioMed Holdings's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orchestra BioMed Holdings (OBIO) has a Market Cap of $220.96 Mil as of Jul. 21, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Orchestra BioMed Holdings and its competitors. According to the industry distribution chart, Orchestra BioMed Holdings ranks #566 out of 1423 companies in the Biotechnology industry, placing it in the top 39.8%.
Is Orchestra BioMed Holdings' Market Cap too high?
Orchestra BioMed Holdings' current Market Cap is $220.96 Mil. The Biotechnology industry median Market Cap is 111.61. Orchestra BioMed Holdings' value of $220.96 Mil is 98% above this industry median. Based on the distribution chart, Orchestra BioMed Holdings ranks #566 out of 1423 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Orchestra BioMed Holdings has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Orchestra BioMed Holdings' Market Cap compare to FULC and OTLK?
According to the Biotechnology industry distribution chart, Orchestra BioMed Holdings ranks #566 out of 1423 companies for Market Cap. This puts Orchestra BioMed Holdings in the upper half of its industry. The industry median Market Cap is 111.61. Orchestra BioMed Holdings' value of $220.96 Mil is 98% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 111.61, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orchestra BioMed Holdings's current Market Cap of $220.96 Mil is 98% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Orchestra BioMed Holdings and its competitors. For the Biotechnology industry, the median Market Cap is 111.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orchestra BioMed Holdings's current Market Cap is $220.96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orchestra BioMed Holdings stock overvalued right now?
Based on GuruFocus' analysis, Orchestra BioMed Holdings (OBIO) is currently considered Possible Value Trap. The stock's GF Value™ is $34.91, compared to a current price of $3.69 — trading 89.4% below its estimated fair value. The current Market Cap is $220.96 Mil and 98% above the Biotechnology industry median of 111.61. Orchestra BioMed Holdings' overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Orchestra BioMed Holdings (OBIO), the current Market Cap is $220.96 Mil as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orchestra BioMed Holdings (OBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Orchestra BioMed Holdings stock appears to be undervalued.
The current stock price of $3.69 is trading 89.4% below its estimated GF Value™ of $34.91.
GuruFocus considers Orchestra BioMed Holdings to be Possible Value Trap.
Key valuation signals for OBIO:
Market Cap: $220.96 Mil
GF Value™: $34.91 vs. price of $3.69 (89.4% below fair value)
Industry Position: 98% above the Biotechnology median (#566 of 1423)
No single metric tells the full story. See the OBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.
44GF Score
Get the complete analysis for OBIO
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OBIO has been successfully added to your 
